title: Performance of serum-supplemented and serum-free media in IFNgamma Elispot Assays for human T cells.
abstract: The choice of serum for supplementation of media for T cell assays and in particular, Elispot has been a major challenge for assay performance, standardization, optimization, and reproducibility. The Assay Working Group of the Cancer Vaccine Consortium (CVC-CRI) has recently identified the choice of serum to be the leading cause for variability and suboptimal performance in large international Elispot proficiency panels. Therefore, a serum task force was initiated to compare the performance of commercially available serum-free media to laboratories' own medium/serum combinations. The objective of this project was to investigate whether a serum-free medium exists that performs as well as lab-own serum/media combinations with regard to antigen-specific responses and background reactivity in Elispot. In this way, a straightforward solution could be provided to address the serum challenge. Eleven laboratories tested peripheral blood mononuclear cells (PBMC) from four donors for their reactivity against two peptide pools, following their own Standard Operating Procedure (SOP). Each laboratory performed five simultaneous experiments with the same SOP, the only difference between the experiments was the medium used. The five media were lab-own serum-supplemented medium, AIM-V, CTL, Optmizer, and X-Vivo. The serum task force results demonstrate compellingly that serum-free media perform as well as qualified medium/serum combinations, independent of the applied SOP. Recovery and viability of cells are largely unaffected by serum-free conditions even after overnight resting. Furthermore, one serum-free medium was identified that appears to enhance antigen-specific IFNgamma-secretion.
authors.affiliation: Cancer Vaccine Consortium of the Cancer Research Institute, New York, NY, USA. sylvia@zellnet.com
authors.forename: Sylvia
authors.initials: S
authors.lastname: Janetzki
authors.forename: L
authors.initials: L
authors.lastname: Price
authors.forename: C M
authors.initials: CM
authors.lastname: Britten
authors.forename: S H
authors.initials: SH
authors.lastname: van der Burg
authors.forename: J
authors.initials: J
authors.lastname: Caterini
authors.forename: J R
authors.initials: JR
authors.lastname: Currier
authors.forename: G
authors.initials: G
authors.lastname: Ferrari
authors.forename: C
authors.initials: C
authors.lastname: Gouttefangeas
authors.forename: P
authors.initials: P
authors.lastname: Hayes
authors.forename: E
authors.initials: E
authors.lastname: Kaempgen
authors.forename: V
authors.initials: V
authors.lastname: Lennerz
authors.forename: K
authors.initials: K
authors.lastname: Nihlmark
authors.forename: V
authors.initials: V
authors.lastname: Souza
authors.forename: A
authors.initials: A
authors.lastname: Hoos
mesh_terms: D019411:Clinical Laboratory Techniques / Q000592:standards* / Q000706:statistics & numerical data; D016895:Culture Media, Serum-Free / Q000494:pharmacology*; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods*; D006801:Humans; D007118:Immunoassay / Q000379:methods* / Q000592:standards; D007371:Interferon-gamma / Q000276:immunology*; D007963:Leukocytes, Mononuclear / Q000276:immunology*; D012015:Reference Standards; D013601:T-Lymphocytes / Q000276:immunology*
chemical_list: D016895:Culture Media, Serum-Free; D007371:Interferon-gamma